West Pharmaceutical Services vs Dentsply Sirona
Dentsply Sirona is the larger business, with $3.68bn of revenue in fiscal 2025 against $3.07bn for West Pharmaceutical Services (1.2 times as much). West Pharmaceutical Services grew faster (6.3% against -3.0%). West Pharmaceutical Services kept more of each dollar of sales as profit: a net margin of 16.1% against -16.3%. West Pharmaceutical Services carries less debt relative to equity (6.4% against 173.9%).
| Latest fiscal year | West Pharmaceutical ServicesWST, 2025 | Dentsply SironaXRAY, 2025 |
|---|---|---|
| Revenue | $3.07bn | $3.68bn |
| Revenue growth | 6.3% | -3.0% |
| Net income | $494m | −$598m |
| Operating margin | 19.0% | -11.5% |
| Net margin | 16.1% | -16.3% |
| Return on equity | 16.9% | -36.5% |
| Free cash flow | $469m | $104m |
| Cash | $791m | $326m |
| Total debt | $203m | $2.33bn |
| Debt to equity | 6.4% | 173.9% |
| Dividend per share | $0.86 | $0.64 |
| Dividend yield | 0.2% | 4.9% |
| Share buybacks | $134m | $0 |
| Employees | — | 14,000 |
| Market value | $28.63bn | $1.93bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 77 (Strong) | 62 (Moderate) |
| Insider trades, 12 months | 0 buys, 8 sales | 12 buys, 1 sales |